Application Deadline
February 29, 2020

Junior Scientist / Molecular Biology

Today, there is a need for more accurate and personalized RNA-based cancer diagnostics. RNA visualization and sequencing are an integrated part of R&D programs in the pharmaceutical industry, and are increasingly used at cancer centers, institutes, and hospitals to provide more accurate diagnosis and subsequent personalized treatment regimens for patients.

Our biotech company, MultiplexDX, aims to drastically increase the number of cancer survivors through personalized diagnostics that lead to tailored, effective, and life-saving treatment. We want to bring to market an accurate, precise, quantitative, cost-effective, and multiplexed diagnostic test for cancer.

The position

We are looking for a Junior Scientist Molecular Biology to join our team in planning, conducting, and optimizing RNA-based diagnostic experiments.

In this multifaceted role, you will help advance our next pipeline of designed diagnostic products, solve technical obstacles, test different concepts in the laboratory, read scientific papers, and generate new ideas in collaboration with our innovative team.

You will report to the Director of Research & Development and Chief Operating Officer and be based at the headquarters in Bratislava, Slovakia.

MultiplexDX received an EIC Accelerator grant, which guarantees two years of funding for this position with the possibility of an extension.


  • Plan, conduct, and optimize RNA-based fluorescent in situ hybridization (FISH) and next-generation sequencing (NGS) experiments;
  • Perform molecular biology techniques, including RNA extraction/purification, PCR, qPCR, RNA/small RNA NGS library preparation, RNA quality control (NanoDrop™, Qubit™, Bioanalyzer/Tapestation), gel electrophoresis, etc.;
  • Use fluorescence microscopy/confocal microscopy to image RNA-FISH tissue
  • Perform routine histopathological examination of tissues, including tissue processing/preparation (e.g., paraffin-embedding, microtome sectioning) and histological staining (e.g., hematoxylin and eosin staining);  
  • Operate and maintain laboratory & analytical equipment;
  • Generate new concepts and ideas in collaboration with the team;
  • Test concepts in the laboratory;
  • Document experimental work, analyze data, document and present results;
  • Prepare written methods and SOPs;
  • Evaluate and document the new product or method;
  • Present research findings in manuscripts, at conferences, and to potential partners;
  • Stay abreast of recent developments in RNA-FISH and RNA NGS and their applications in clinical diagnostics.


  • Bachelor’s or Master’s degree in Molecular Biology (or related field)
  • Practical laboratory experience in RNA-FISH and/or next-generation sequencing is an advantage;
  • Hands-on laboratory experience with RNA-FISH, NGS library preparation, and other molecular biology techniques (PCR, qPCR, gel electrophoresis) from academia, biotech or similar industry is preferred;
  • Ability to work independently as well as part of a multidisciplinary team is essential;
  • Excellent analytical and systematic troubleshooting skills;
  • Strong creative skills and out-of-the-box thinking;
  • Demonstration of goal-oriented, hands-on, and innovative approach to problem solving;
  • Excellent written and oral communication skills (English is our working language);
  • Excellent organizational and reasoning skills are a must.

We offer

We offer a great career with development opportunities in a highly motivating and professional environment. You may be looking for a new career path or simply looking to contribute to a small, hard-working organization with the ambition to make a difference.

You will be offered the opportunity to spearhead the next ground-breaking diagnostic technologies involving RNA-based next-generation sequencing.

The job will be challenging and rewarding at the same time. You will have world class colleagues, flexible working hours, 5 weeks of paid holiday, and a negotiable salary commensurate to your qualifications (starting from €1500/month). This position will be funded for at least two years with the possibility of an extension under a recently awarded EIC Accelerator grant.

Application deadline

Application deadline is February 29th, 2020. Please send the application including your CV or resume with the names of 3 references and a cover letter to

Your application will be treated in accordance with our policies for processing of personal data and the General Data Protection Regulation of the EU.


MultiplexDX’s diagnostic products combine specific, precise, automated, high-throughput, multiplexed and quantitative RNA visualization and sequencing to come up with a specific “barcode” for each cancer, which suggests a unique, personalized treatment strategy. In MultiplexDX’s diagnostic tests, multiplexing stands for cross-validating test results by using two independent perspectives, visualization and sequencing. This multiplexed platform provides the most accurate clinical parameters of a patient’s cancer profile, which enables an oncologist to make an evidence-based decision and target treatment quickly, directly, and more accurately.

For additional information, please contact

Peter Kilian
Ilkovičova 8
84104 Bratislava, Slovakia

About MultiplexDX

MultiplexDX is one of the most innovative biotech corporations, created to bring its revolutionary technologies to the market of personalized molecular diagnostics. The company has representation in both U.S. and European markets. The collaborators of MultiplexDX are from the world’s most prestigious scientific organizations including the National Cancer Institute, Rockefeller University, Albert Einstein University, Vanderbilt University, Cornell University, Queens University (Canada), Hebrew University of Jerusalem (Israel), and the Max Delbrück Center for Molecular Medicine (Germany).

MultiplexDX IP-based and innovative platform merges histopathology methods, biomarker quantification, visualization and gene expression with a single-cell resolution by combining MDX proprietary visual and sequencing technologies into one diagnostic test. This cross-validation approach eliminates diagnostic errors and creates 100% precise cancer profiling for each patient which allows clinicians to suggest specific, personalized cancer treatment.

Find out more about MultiplexDX on Corporate website, Facebook, LinkedIn, Twitter